ARTMS and Telix Pharmaceuticals Announce Successful Production of PSMA-11 with Cyclotron Produced 68Ga from a Solid Target
January 12 2021 - 08:00AM
Business Wire
ARTMS Inc. (‘ARTMS’) and Telix Pharmaceuticals
Limited (ASX: TLX, ‘Telix’) are pleased to announce they have
successfully produced Telix’s prostate cancer imaging product,
TLX591-CDx (Kit for the preparation of 68Ga-PSMA-11)1, using
multi-Curie quantities of cyclotron-produced Gallium-68 (68Ga) via
ARTMS’ proprietary Quantum Irradiation System (QIS®) solid target
system.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210112005019/en/
The testing demonstrated an impressive six-hour stability of
TLX591-CDx, a radiopharmaceutical targeting Prostate-Specific
Membrane Antigen (PSMA) for the imaging of prostate cancer using
Positron Emission Tomography (PET). Testing exceeded all relevant
quality control standards for both low- (50 mCi and 100 mCi) and
mid-level output (over 2,500 mCi) 68Ga production runs. The “cold
kit” format of TLX591-CDx enables rapid radiolabelling at room
temperature with high radiochemical purity and production
consistency, ideally suited for the radiopharmacy setting.
ARTMS Chief Executive Officer, Charles S. Conroy, stated, “This
collaboration and successful testing represents a significant step
forward for the diagnosis of prostate cancer globally. The
combination of Telix’s user friendly, high quality PSMA-11 kit
along with robust production of 68Ga using our solid targetry
approach moves us closer to having a PET diagnostic agent on demand
for clinicians. Our goal at ARTMS is to ensure that the 68Ga supply
is able to meet the substantial projected clinical demand for this
isotope.”
Telix USA President, Dr Bernard Lambert, added, “When the
Telix-ARTMS collaboration was announced in April 2020, we were
confident that ARTMS’ proprietary technology to produce 68Ga from
specialized solid 68Zn targets using low-energy cyclotrons would be
valuable to the Molecular Imaging and Oncology community. ARTMS’
work represents a significant development in how 68Ga is able to be
supplied to the market for large-scale production and, as a result,
will contribute to the reliability of access to all men living with
prostate cancer who require advanced prostate imaging. This outcome
is a testament to both the ARTMS technology and Telix’s proprietary
formulation of PSMA-11”
ARTMS will continue the development of cyclotron-produced 68Ga
with a focus on optimizing production potential and satisfying
regulatory requirements for use in radiopharmaceutical kits such as
TLX591-CDx.
About Prostate Cancer
Prostate cancer is the second most common cancer in men
following skin cancer and, in 2018, 1.3 million men were diagnosed
with prostate cancer for the first time.2 Despite advances in
treatment, prostate cancer still accounts for a large number of
deaths and in 2018 more than 365,000 men died from their disease.
Rates of diagnosis are increasing, with the highest incidences of
prostate cancer occurring in the United States, Europe, and
Australia and New Zealand.
About ARTMS
Based in Vancouver, British Columbia, Canada, ARTMS Inc. is a
global leader in the development of novel technologies and products
which enable the high-quality and high-yield production of the
world’s most-used diagnostic imaging isotopes. ARTMS’ flagship
product, the QUANTM Irradiation SystemTM (QISTM), enables
decentralized, cost-effective, large-scale production of important
medical isotopes such as Gallium-68 (68Ga), zirconium-89 (89Zr),
technetium‐99m (99mTc) and copper-64 (64Cu) using pharmaceutical
distributor and hospital-based medical cyclotrons, empowering users
to control their supply chain. ARTMS commercializes these
award-winning and proprietary Canadian inventions on a global basis
and has the prospect of revolutionizing the nuclear medicine
industry. For more information on the QUANTM Irradiation System™
and ARTMS, please follow us on Twitter @Quantm99 and LinkedIn and
visit http://www.artms.ca/.
About Telix Pharmaceuticals Limited
Telix is a clinical-stage biopharmaceutical company focused on
the development of diagnostic and therapeutic products using
Molecularly Targeted Radiation (MTR). Telix is headquartered in
Melbourne, Australia with international operations in Belgium,
Japan and the United States. Telix is developing a portfolio of
clinical-stage oncology products that address significant unmet
medical needs in oncology and rare diseases. Telix is listed on the
Australian Securities Exchange (ASX: TLX). For more information
visit www.telixpharma.com.
_________________ 1 TLX591-CDx is not currently approved in any
jurisdiction including the United States, Canada and the European
Union. 2 GLOBOCAN 2018.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210112005019/en/
ARTMS Corporate Contact Charles S. Conroy R.Ph, MBA
ARTMS, Inc. Chief Executive Officer Email: conroy@artms.ca
ARTMS Business Contact Doug Gentilcore ARTMS, Inc. Chief
Commercial Officer Email: gentilcore@artms.ca
Telix Corporate Contact Dr. Christian Behrenbruch Telix
Pharmaceuticals Limited Chief Executive Officer Email:
chris@telixpharma.com
Telix Business Contact Dr. David N. Cade Telix
Pharmaceuticals Limited Chief Business Officer Email:
david.cade@telixpharma.com
Telix Pharmaceuticals (ASX:TLX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Telix Pharmaceuticals (ASX:TLX)
Historical Stock Chart
From Mar 2023 to Mar 2024